[lurkingforacure]

I was pleasantly surprised to read about this in Scientific American, August issue, and more importantly, at the end of the article they list several allosteric drugs "in the pipeline and on tap", as follows (there are others, I'm just listing what I think is relevant to us):

Alzheimer's: XY4083, first human trials expected to start early this year
this drug enhances the activity of alpha7 subtype of nicotinic acetylcholine receptor

PD: ADX 48621, "in early trials"
PD: AFQ056, also "in early trials"
both of these candidates inhibit metabotropic glutamate receptor 5

Coincidentally, ADX48621 just reached its second milestone and Addex receives a second installment of 500K for same, here's the news article I found on this:

http://pr-usa.net/index.php?option=c...6146&Itemid=28